Analysis of Retinal Vessel Reaction and Monitoring of Circulation Parameters During Bevacizumab Therapy
N/A
18 Years
N/A
18 Years
N/A
Open (Enrolling)
Both
Cancer
Both
Cancer
Trial Information
Analysis of Retinal Vessel Reaction and Monitoring of Circulation Parameters During Bevacizumab Therapy
By monitoring different vessel and circulation parameters (e.g. dynamic retinal vessel
analyzer) the study will clarify the potential hemodynamic effects of bevacizumab.
Inclusion Criteria:
- patients who wish and need bevacizumab treatment for underlying disease
Exclusion Criteria:
- previous bevacizumab treatment
- known eye disease, eye surgery or eye trauma in history
- myopia >-2.0 dpt
- hyperopia > +2.0 dpt.
- relevant media opacity of the lens
- acute heart disease, ischemic insult, proven coronary heart disease
- cardiac arrhythmia or vessel anomalies
- seizure disorder or episode in history
- migraine
- treatment with corticosteroids within 4 weeks before study inclusion
- intake of vasoactive drugs like AT-1 or glitazone
- pregnancy
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
Diameter of retinal vessels and dynamic vessel reaction
Outcome Time Frame:
Measurements before and after administration
Safety Issue:
Yes
Principal Investigator
Tjalf Ziemssen, MD
Investigator Role:
Principal Investigator
Investigator Affiliation:
Neurological University Clinic
Authority:
Germany: Ethics Commission
Study ID:
B-ANF1
NCT ID:
NCT00740168
Start Date:
May 2007
Completion Date:
April 2009
Related Keywords:
- Cancer
- bevacizumab
- cancer
Name | Location |
|---|
